MPV17L2

Across TCGA pan-cancer cohorts, MPV17L2 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated MPV17L2 data layer.

The strongest signal is observed in uveal melanoma (UVM), where higher MPV17L2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MPV17L2 expression acts as an unfavorable survival marker, although some lineages such as SCLC and CESC show a favorable association.

UVM, SCLC, and KIRC are the cancer types where MPV17L2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Median	All	0.423	0.776	<.001	142	view →
SCLC	OS	Median	All	0.722	0.426	<.001	104	view →
KIRC	DFS	Median	All	0.828	0.913	<.001	79	view →
ACC	OS	Median	All	0.779	0.959	<.001	59	view →
CESC	OS	Median	All	0.914	0.828	.005	54	view →
LGG	OS	Median	All	0.743	0.879	<.001	50	view →
KICH	DFS	Tertile	All	0.749	1.000	.008	48	view →
UCS	DFS	Median	III,IV	0.145	0.520	.003	40	view →
LAML	DFS	Quartile	All	0.329	0.779	<.001	30	view →
SKCM	DFS	Median	All	0.667	0.834	.003	24	view →
HNSC	DFS	Quartile	IV	0.602	0.314	.006	23	view →
LIHC	OS	Median	All	0.461	0.667	.009	19	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

MPV17L2–UVM (OS)

Open the UVM breakdown →